BioCryst Pharmaceuticals, Inc. (BCRX)
USD 6.47
(-4.71%)
USD 6.47
(-4.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -226.53 Million USD | 8.33% |
| 2022 | -247.11 Million USD | -34.26% |
| 2021 | -184.06 Million USD | 6.36% |
| 2020 | -196.56 Million USD | -63.72% |
| 2019 | -120.06 Million USD | -18.58% |
| 2018 | -101.25 Million USD | -53.92% |
| 2017 | -65.78 Million USD | -19.29% |
| 2016 | -55.14 Million USD | -28.19% |
| 2015 | -43.01 Million USD | 4.8% |
| 2014 | -45.18 Million USD | -50.09% |
| 2013 | -30.1 Million USD | 22.96% |
| 2012 | -39.08 Million USD | 31.37% |
| 2011 | -56.94 Million USD | -73.98% |
| 2010 | -32.73 Million USD | -143.33% |
| 2009 | -13.45 Million USD | 45.61% |
| 2008 | -24.73 Million USD | 14.88% |
| 2007 | -29.05 Million USD | 33.39% |
| 2006 | -43.61 Million USD | -67.13% |
| 2005 | -26.09 Million USD | -23.67% |
| 2004 | -21.1 Million USD | -66.17% |
| 2003 | -12.7 Million USD | 24.98% |
| 2002 | -16.92 Million USD | -239.53% |
| 2001 | -4.98 Million USD | 56.94% |
| 2000 | -11.57 Million USD | -118.45% |
| 1999 | -5.3 Million USD | -10.42% |
| 1998 | -4.8 Million USD | 54.72% |
| 1997 | -10.6 Million USD | -37.66% |
| 1996 | -7.7 Million USD | 10.47% |
| 1995 | -8.6 Million USD | -24.64% |
| 1994 | -6.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -35.37 Million USD | 42.69% |
| 2024 Q2 | -12.67 Million USD | 64.18% |
| 2024 Q3 | -14.03 Million USD | -10.72% |
| 2023 Q3 | -36.14 Million USD | 52.01% |
| 2023 Q1 | -53.33 Million USD | 25.45% |
| 2023 Q2 | -75.32 Million USD | -41.24% |
| 2023 FY | -226.53 Million USD | 8.33% |
| 2023 Q4 | -61.73 Million USD | -70.77% |
| 2022 FY | -247.11 Million USD | -34.26% |
| 2022 Q1 | -74.19 Million USD | -317.32% |
| 2022 Q2 | -58.85 Million USD | 20.67% |
| 2022 Q3 | -42.52 Million USD | 27.76% |
| 2022 Q4 | -71.54 Million USD | -68.25% |
| 2021 Q4 | -17.77 Million USD | 69.76% |
| 2021 FY | -184.06 Million USD | 6.36% |
| 2021 Q1 | -64.28 Million USD | -6.27% |
| 2021 Q2 | -43.19 Million USD | 32.8% |
| 2021 Q3 | -58.8 Million USD | -36.12% |
| 2020 FY | -196.56 Million USD | -63.72% |
| 2020 Q1 | -37.59 Million USD | -1333.98% |
| 2020 Q2 | -38.6 Million USD | -2.68% |
| 2020 Q3 | -46.11 Million USD | -19.45% |
| 2020 Q4 | -60.49 Million USD | -31.18% |
| 2019 Q4 | -2.62 Million USD | 93.03% |
| 2019 Q3 | -37.59 Million USD | 0.1% |
| 2019 Q1 | -31.05 Million USD | -13.2% |
| 2019 Q2 | -37.62 Million USD | -21.17% |
| 2019 FY | -120.06 Million USD | -18.58% |
| 2018 Q2 | -18.44 Million USD | 28.44% |
| 2018 FY | -101.25 Million USD | -53.92% |
| 2018 Q1 | -25.77 Million USD | -31.9% |
| 2018 Q3 | -29.59 Million USD | -60.45% |
| 2018 Q4 | -27.43 Million USD | 7.31% |
| 2017 Q3 | -15.13 Million USD | 10.38% |
| 2017 FY | -65.78 Million USD | -19.29% |
| 2017 Q1 | -14.21 Million USD | -215.77% |
| 2017 Q4 | -19.54 Million USD | -29.13% |
| 2017 Q2 | -16.88 Million USD | -18.76% |
| 2016 Q1 | -22.83 Million USD | -25.9% |
| 2016 Q4 | -4.5 Million USD | 60.94% |
| 2016 FY | -55.14 Million USD | -28.19% |
| 2016 Q3 | -11.52 Million USD | 29.19% |
| 2016 Q2 | -16.28 Million USD | 28.69% |
| 2015 Q4 | -18.13 Million USD | -24.03% |
| 2015 Q2 | 4.9 Million USD | 132.32% |
| 2015 Q1 | -15.16 Million USD | -29.92% |
| 2015 FY | -43.01 Million USD | 4.8% |
| 2015 Q3 | -14.62 Million USD | -398.33% |
| 2014 FY | -45.18 Million USD | -50.09% |
| 2014 Q4 | -11.67 Million USD | -33.68% |
| 2014 Q3 | -8.73 Million USD | 40.4% |
| 2014 Q2 | -14.64 Million USD | -44.51% |
| 2014 Q1 | -10.13 Million USD | -86.72% |
| 2013 Q1 | -4.5 Million USD | 59.23% |
| 2013 Q3 | -8 Million USD | 34.27% |
| 2013 Q4 | -5.42 Million USD | 32.15% |
| 2013 FY | -30.1 Million USD | 22.96% |
| 2013 Q2 | -12.17 Million USD | -170.13% |
| 2012 FY | -39.08 Million USD | 31.37% |
| 2012 Q2 | -12.27 Million USD | -102.84% |
| 2012 Q3 | -9.7 Million USD | 20.98% |
| 2012 Q4 | -11.05 Million USD | -13.95% |
| 2012 Q1 | -6.05 Million USD | 54.12% |
| 2011 Q1 | -13.02 Million USD | -27.7% |
| 2011 Q2 | -16.27 Million USD | -24.9% |
| 2011 Q3 | -14.45 Million USD | 11.14% |
| 2011 Q4 | -13.19 Million USD | 8.76% |
| 2011 FY | -56.94 Million USD | -73.98% |
| 2010 Q4 | -10.2 Million USD | 6.1% |
| 2010 FY | -32.73 Million USD | -143.33% |
| 2010 Q3 | -10.86 Million USD | -6.58% |
| 2010 Q1 | -2.59 Million USD | -117.13% |
| 2010 Q2 | -10.19 Million USD | -292.79% |
| 2009 Q3 | -10.62 Million USD | -22.37% |
| 2009 Q1 | -9.29 Million USD | -192.27% |
| 2009 FY | -13.45 Million USD | 45.61% |
| 2009 Q4 | 15.15 Million USD | 242.58% |
| 2009 Q2 | -8.68 Million USD | 6.54% |
| 2008 FY | -24.73 Million USD | 14.88% |
| 2008 Q4 | 10.07 Million USD | 211.96% |
| 2008 Q3 | -8.99 Million USD | 29.22% |
| 2008 Q2 | -12.7 Million USD | 2.97% |
| 2008 Q1 | -13.09 Million USD | -473.59% |
| 2007 Q3 | -10.98 Million USD | -57.75% |
| 2007 Q2 | -6.96 Million USD | 21.1% |
| 2007 Q1 | -8.82 Million USD | 12.19% |
| 2007 FY | -29.05 Million USD | 33.39% |
| 2007 Q4 | -2.28 Million USD | 79.21% |
| 2006 Q2 | -10.08 Million USD | -27.92% |
| 2006 Q1 | -7.88 Million USD | -10.07% |
| 2006 FY | -43.61 Million USD | -67.13% |
| 2006 Q4 | -10.04 Million USD | 35.59% |
| 2006 Q3 | -15.6 Million USD | -54.75% |
| 2005 Q4 | -7.16 Million USD | 6.33% |
| 2005 Q3 | -7.64 Million USD | -35.36% |
| 2005 Q2 | -5.64 Million USD | -0.05% |
| 2005 FY | -26.09 Million USD | -23.67% |
| 2005 Q1 | -5.64 Million USD | -6.73% |
| 2004 Q3 | -5.29 Million USD | -4.73% |
| 2004 Q2 | -5.05 Million USD | 7.41% |
| 2004 Q4 | -5.28 Million USD | 0.13% |
| 2004 FY | -21.1 Million USD | -66.17% |
| 2004 Q1 | -5.46 Million USD | -68.06% |
| 2003 Q3 | -3.4 Million USD | -4.83% |
| 2003 Q4 | -3.25 Million USD | 4.66% |
| 2003 Q2 | -3.25 Million USD | -16.64% |
| 2003 Q1 | -2.78 Million USD | -1.91% |
| 2003 FY | -12.7 Million USD | 24.98% |
| 2002 FY | -16.92 Million USD | -239.53% |
| 2002 Q4 | -2.73 Million USD | 19.89% |
| 2002 Q3 | -3.41 Million USD | 33.83% |
| 2002 Q2 | -5.16 Million USD | 8.1% |
| 2002 Q1 | -5.61 Million USD | -12.82% |
| 2001 Q3 | 417 Thousand USD | -56.47% |
| 2001 FY | -4.98 Million USD | 56.94% |
| 2001 Q1 | -1.38 Million USD | 85.88% |
| 2001 Q2 | 958 Thousand USD | 169.27% |
| 2001 Q4 | -4.97 Million USD | -1293.76% |
| 2000 Q3 | -1.64 Million USD | 17.64% |
| 2000 FY | -11.57 Million USD | -118.45% |
| 2000 Q4 | -9.79 Million USD | -496.34% |
| 2000 Q2 | -1.99 Million USD | -207.37% |
| 2000 Q1 | 1.85 Million USD | 564.54% |
| 1999 Q4 | -400 Thousand USD | 81.82% |
| 1999 FY | -5.3 Million USD | -10.42% |
| 1999 Q3 | -2.2 Million USD | -633.33% |
| 1999 Q2 | -300 Thousand USD | 87.5% |
| 1999 Q1 | -2.4 Million USD | -60.0% |
| 1998 Q1 | -3 Million USD | -3.45% |
| 1998 Q4 | -1.5 Million USD | -155.56% |
| 1998 Q3 | 2.7 Million USD | 190.0% |
| 1998 Q2 | -3 Million USD | 0.0% |
| 1998 FY | -4.8 Million USD | 54.72% |
| 1997 Q1 | -3.1 Million USD | -47.62% |
| 1997 FY | -10.6 Million USD | -37.66% |
| 1997 Q4 | -2.9 Million USD | -16.0% |
| 1997 Q3 | -2.5 Million USD | -19.05% |
| 1997 Q2 | -2.1 Million USD | 32.26% |
| 1996 Q2 | -1.2 Million USD | 36.84% |
| 1996 Q1 | -1.9 Million USD | 13.64% |
| 1996 FY | -7.7 Million USD | 10.47% |
| 1996 Q4 | -2.1 Million USD | 16.0% |
| 1996 Q3 | -2.5 Million USD | -108.33% |
| 1995 Q1 | -2.9 Million USD | -61.11% |
| 1995 FY | -8.6 Million USD | -24.64% |
| 1995 Q3 | -1.9 Million USD | -18.75% |
| 1995 Q4 | -2.2 Million USD | -15.79% |
| 1995 Q2 | -1.6 Million USD | 44.83% |
| 1994 Q1 | -1.6 Million USD | 0.0% |
| 1994 Q3 | -1.6 Million USD | 15.79% |
| 1994 Q4 | -1.8 Million USD | -12.5% |
| 1994 FY | -6.9 Million USD | 0.0% |
| 1994 Q2 | -1.9 Million USD | -18.75% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -51.92 Million USD | -336.281% |
| Jaguar Health, Inc. | -41.3 Million USD | -448.521% |
| Keros Therapeutics, Inc. | -152.99 Million USD | -48.072% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | -316.264% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 48.542% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 534.366% |
| ContextLogic Inc. | -317 Million USD | 28.537% |
| MiMedx Group, Inc. | 67.43 Million USD | 435.917% |
| MEI Pharma, Inc. | 17.77 Million USD | 1374.266% |
| AlloVir, Inc. | -190.41 Million USD | -18.969% |
| Novavax, Inc. | -545.06 Million USD | 58.438% |
| Aptorum Group Limited | -2.82 Million USD | -7920.082% |
| Ardelyx, Inc. | -66.06 Million USD | -242.893% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | -10.359% |
| Psyence Biomedical Ltd. | -51.15 Million USD | -342.813% |
| Vaxcyte, Inc. | -402.26 Million USD | 43.684% |
| Precigen, Inc. | -95.9 Million USD | -136.214% |
| Pharming Group N.V. | -10.54 Million USD | -2047.696% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | -12.375% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | -823.029% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | -802.87% |
| Avidity Biosciences, Inc. | -212.22 Million USD | -6.747% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | -1121.492% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -830.754% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -830.754% |
| Bicycle Therapeutics plc | -180.66 Million USD | -25.392% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 12.137% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | -731.702% |
| Acelyrin, Inc. | -381.64 Million USD | 40.641% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | -506.693% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | -564.318% |
| Senti Biosciences, Inc. | -92.91 Million USD | -143.803% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | -116.372% |
| AbCellera Biologics Inc. | -146.39 Million USD | -54.742% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | -544.676% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | -26.521% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -3288.766% |
| Chimerix, Inc. | -82.09 Million USD | -175.947% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | -671.538% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -1016.451% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -407.897% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -343.69% |
| Elevation Oncology, Inc. | -45.7 Million USD | -395.666% |
| Alkermes plc | 355.75 Million USD | 163.678% |
| Fortress Biotech, Inc. | -60.63 Million USD | -273.599% |
| Fortress Biotech, Inc. | -60.63 Million USD | -273.599% |
| Agenus Inc. | -245.76 Million USD | 7.821% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | -177.689% |
| Dyadic International, Inc. | -6.79 Million USD | -3233.681% |
| ImmuCell Corporation | -5.77 Million USD | -3823.026% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -24102.885% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | -100.546% |
| Lantern Pharma Inc. | -15.96 Million USD | -1319.281% |
| Immix Biopharma, Inc. | -15.42 Million USD | -1368.549% |
| Incyte Corporation | 597.59 Million USD | 137.908% |
| IO Biotech, Inc. | -86.08 Million USD | -163.163% |
| Janux Therapeutics, Inc. | -58.29 Million USD | -288.621% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | -1090.501% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | -284.077% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | -37.652% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -2564.851% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | -208.859% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 39.368% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 60.454% |
| NextCure, Inc. | -62.72 Million USD | -261.174% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -2168.566% |
| Onconetix, Inc. | -37.4 Million USD | -505.562% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | -473.822% |
| Opthea Limited | -220.24 Million USD | -2.859% |
| PDS Biotechnology Corporation | -42.94 Million USD | -427.544% |
| PureTech Health plc | -65.69 Million USD | -244.824% |
| Pyxis Oncology, Inc. | -73.79 Million USD | -207.005% |
| Seer, Inc. | -86.27 Million USD | -162.572% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -1806043.658% |
| Clearside Biomedical, Inc. | -32.48 Million USD | -597.365% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | -1633.028% |
| VYNE Therapeutics Inc. | -28.45 Million USD | -696.215% |
| Wave Life Sciences Ltd. | -57.51 Million USD | -293.892% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -263.889% |
| C4 Therapeutics, Inc. | -132.49 Million USD | -70.982% |
| ChromaDex Corporation | -4.93 Million USD | -4487.667% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -6213.796% |
| Caribou Biosciences, Inc. | -102.07 Million USD | -121.945% |
| CRISPR Therapeutics AG | -153.61 Million USD | -47.477% |
| Precision BioSciences, Inc. | -61.31 Million USD | -269.443% |
| Fate Therapeutics, Inc. | -160.92 Million USD | -40.77% |
| Innoviva, Inc. | 179.72 Million USD | 226.05% |
| Summit Therapeutics Inc. | -614.92 Million USD | 63.16% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | -238.143% |
| Aadi Bioscience, Inc. | -65.76 Million USD | -244.467% |
| ESSA Pharma Inc. | -26.58 Million USD | -752.216% |
| GlycoMimetics, Inc. | -36.89 Million USD | -513.936% |
| GT Biopharma, Inc. | -7.59 Million USD | -2881.953% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 6.141% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 417.237% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | -361.195% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -2177.29% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 7.759% |
| Aptose Biosciences Inc. | -51.2 Million USD | -342.399% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | -130.462% |
| Soligenix, Inc. | -6.14 Million USD | -3589.122% |
| Century Therapeutics, Inc. | -136.67 Million USD | -65.753% |
| Kura Oncology, Inc. | -152.63 Million USD | -48.423% |
| TScan Therapeutics, Inc. | -89.21 Million USD | -153.916% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -2049.734% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 40162.072% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -39713.533% |
| Autolus Therapeutics plc | -208.38 Million USD | -8.713% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | -215.084% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | -219.993% |
| Eterna Therapeutics Inc. | -21.66 Million USD | -945.5% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | -0.572% |
| GRI Bio, Inc. | -13.03 Million USD | -1637.662% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -5379.132% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | -82.569% |
| IGM Biosciences, Inc. | -246.41 Million USD | 8.066% |
| INmune Bio, Inc. | -30 Million USD | -654.929% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -104.903% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -436.901% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -1319.27% |
| Entero Therapeutics, Inc. | -15.79 Million USD | -1334.247% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | -279.558% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | -123.926% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 17.958% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 4.772% |
| Verastem, Inc. | -87.36 Million USD | -159.296% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -318.061% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | -40.414% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | -94.191% |
| Histogen Inc. | -10.62 Million USD | -2032.935% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | -1485.657% |
| Surrozen, Inc. | -43.04 Million USD | -426.321% |
| Organovo Holdings, Inc. | -14.67 Million USD | -1444.128% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -4353.267% |
| Ovid Therapeutics Inc. | -52.33 Million USD | -332.831% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -796.722% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | -740.964% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -2610.742% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | -49.941% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | -363.023% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | -662.116% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -2074.558% |
| Apollomics, Inc. | -172.6 Million USD | -31.25% |
| Amarin Corporation plc | -59.11 Million USD | -283.237% |
| Mesoblast Limited | -87.95 Million USD | -157.559% |
| Turnstone Biologics Corp. | -55.2 Million USD | -310.397% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | -54.148% |
| Synaptogenix, Inc. | -6.03 Million USD | -3651.575% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | -1297.699% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | -190.36% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -4627.968% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -2596.188% |
| Exelixis, Inc. | 207.76 Million USD | 209.036% |
| Better Therapeutics, Inc. | -39.76 Million USD | -469.766% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | -57.376% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 57.146% |
| NLS Pharmaceutics AG | -12.17 Million USD | -1761.144% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -2806.325% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -636.736% |
| Gritstone bio, Inc. | -138.49 Million USD | -63.578% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -251.414% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -5563.546% |
| Avid Bioservices, Inc. | -140.75 Million USD | -60.948% |
| Insmed Incorporated | -749.56 Million USD | 69.777% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | -1391.418% |
| MediWound Ltd. | -6.71 Million USD | -3273.124% |
| OmniAb, Inc. | -50.61 Million USD | -347.537% |
| Alector, Inc. | -130.39 Million USD | -73.738% |
| Seres Therapeutics, Inc. | -113.72 Million USD | -99.201% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | -336.938% |
| Zai Lab Limited | -334.62 Million USD | 32.3% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 30.078% |
| Aura Biosciences, Inc. | -76.4 Million USD | -196.486% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 3.449% |
| Immunic, Inc. | -93.61 Million USD | -141.998% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | -66.704% |
| Veracyte, Inc. | -74.4 Million USD | -204.472% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -2851.437% |
| FibroGen, Inc. | -284.23 Million USD | 20.298% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -763.598% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -3135.398% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | -1102.903% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 154.61% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | -904.385% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 559.782% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1887.713% |
| Galecto, Inc. | -38.34 Million USD | -490.73% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -1100.779% |
| Fortrea Holdings Inc. | -3.4 Million USD | -6562.912% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | -78.879% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | -1201.126% |
| XBiotech Inc. | -24.55 Million USD | -822.503% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -251.414% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | -261.422% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | -130.162% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | -957.26% |
| Theravance Biopharma, Inc. | -55.19 Million USD | -310.449% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 62.657% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | -231.901% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -397797.566% |
| Gain Therapeutics, Inc. | -22.26 Million USD | -917.352% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | -3.108% |
| NexImmune, Inc. | -32.34 Million USD | -600.397% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -4185.176% |
| Marker Therapeutics, Inc. | -14.04 Million USD | -1512.848% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 105.73% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | -835.3% |
| Scopus BioPharma Inc. | -11.6 Million USD | -1851.269% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | -93.958% |
| Ainos, Inc. | -13.77 Million USD | -1545.098% |
| Pluri Inc. | -20.88 Million USD | -984.541% |
| Prothena Corporation plc | -147.02 Million USD | -54.079% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | -98.944% |
| Celularity Inc. | -196.29 Million USD | -15.407% |
| Rallybio Corporation | -74.56 Million USD | -203.818% |
| Cue Biopharma, Inc. | -50.73 Million USD | -346.532% |
| MeiraGTx Holdings plc | -84.02 Million USD | -169.603% |
| Omeros Corporation | -117.81 Million USD | -92.287% |
| Humacyte, Inc. | -110.77 Million USD | -104.502% |
| Immunocore Holdings plc | -55.28 Million USD | -309.751% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | -1159.67% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | -887.916% |
| Blueprint Medicines Corporation | -506.98 Million USD | 55.316% |
| CalciMedica, Inc. | -34.35 Million USD | -559.368% |
| Cabaletta Bio, Inc. | -67.67 Million USD | -234.745% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | -60.206% |
| Scholar Rock Holding Corporation | -165.78 Million USD | -36.643% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 20.023% |
| Pulmatrix, Inc. | -14.12 Million USD | -1504.27% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | -543.668% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | -174.134% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 52.921% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | -116.017% |
| Cytokinetics, Incorporated | -526.24 Million USD | 56.952% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -528.141% |
| Nutriband Inc. | -5.48 Million USD | -4029.919% |
| Protara Therapeutics, Inc. | -40.42 Million USD | -460.463% |
| Vor Biopharma Inc. | -117.86 Million USD | -92.205% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 105.209% |
| Evogene Ltd. | -23.87 Million USD | -848.696% |
| ProKidney Corp. | -35.46 Million USD | -538.714% |
| Applied Therapeutics, Inc. | -119.76 Million USD | -89.156% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -2787.543% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 64.779% |
| CorMedix Inc. | -46.33 Million USD | -388.871% |
| BioLineRx Ltd. | -60.61 Million USD | -273.74% |
| Tango Therapeutics, Inc. | -101.74 Million USD | -122.656% |
| Galectin Therapeutics Inc. | -41.06 Million USD | -451.646% |
| Atai Life Sciences N.V. | -40.22 Million USD | -463.194% |
| Renovaro Biosciences Inc. | -80.65 Million USD | -180.891% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | -199.968% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 22.469% |
| Sagimet Biosciences Inc. | -27.87 Million USD | -712.667% |
| MediciNova, Inc. | -8.57 Million USD | -2542.928% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | -83.764% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -2604.351% |
| GeoVax Labs, Inc. | -25.96 Million USD | -772.419% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 5.308% |
| Biomea Fusion, Inc. | -117.25 Million USD | -93.202% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 63.847% |
| Mereo BioPharma Group plc | -29.46 Million USD | -668.815% |
| Cullinan Oncology, Inc. | -153.16 Million USD | -47.908% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | -8.205% |
| Absci Corporation | -110.56 Million USD | -104.89% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -651.373% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | -124.659% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 3.983% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 1708.485% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | -17.401% |
| Allakos Inc. | -185.7 Million USD | -21.991% |
| Imunon, Inc. | -19.51 Million USD | -1060.847% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | -132.742% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 313.434% |
| BioAtla, Inc. | -123.46 Million USD | -83.489% |
| NLS Pharmaceutics AG | -12.17 Million USD | -1761.144% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -1309.0% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 30.778% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | -513.113% |
| XOMA Corporation | -40.83 Million USD | -454.821% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | -122.38% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -91.151% |
| aTyr Pharma, Inc. | -50.38 Million USD | -349.58% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | -158.373% |
| Akero Therapeutics, Inc. | -151.75 Million USD | -49.275% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 4.709% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | -545.061% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -2699.564% |
| Akari Therapeutics, Plc | -10 Million USD | -2163.579% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -336385.704% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 180.449% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -3298.986% |
| UroGen Pharma Ltd. | -102.24 Million USD | -121.567% |
| Sutro Biopharma, Inc. | -106.79 Million USD | -112.129% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -2812.867% |
| Orgenesis Inc. | -55.36 Million USD | -309.203% |
| Entera Bio Ltd. | -8.88 Million USD | -2448.532% |
| GH Research PLC | -35.58 Million USD | -536.578% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | -987.039% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | -192.731% |
| Xencor, Inc. | -126.08 Million USD | -79.669% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -5915.85% |
| Replimune Group, Inc. | -215.79 Million USD | -4.979% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | -965.237% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 9129.055% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -3298.986% |
| Portage Biotech Inc. | -75.33 Million USD | -200.693% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -2604.351% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | -134.379% |
| OncoCyte Corporation | -27.78 Million USD | -715.446% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | -1588.421% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | -1936.943% |
| Purple Biotech Ltd. | -19.88 Million USD | -1039.532% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -3127.511% |
| scPharmaceuticals Inc. | -54.81 Million USD | -313.317% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | -1194.054% |
| HilleVax, Inc. | -123.56 Million USD | -83.334% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -2141.407% |
| Tharimmune, Inc. | -9.31 Million USD | -2330.912% |
| Genprex, Inc. | -30.86 Million USD | -634.075% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 3.978% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | -652.771% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -12612.626% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -4177.537% |
| OKYO Pharma Limited | -16.82 Thousand USD | -1346305.982% |
| Savara Inc. | -54.69 Million USD | -314.163% |
| Curis, Inc. | -47.41 Million USD | -377.799% |
| Daré Bioscience, Inc. | -30.16 Million USD | -651.089% |
| Carmell Therapeutics Corporation | -15.44 Million USD | -1366.738% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -3967.858% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | -659.816% |
| BeiGene, Ltd. | -881.7 Million USD | 74.307% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -963.863% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 48.085% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | -186.922% |
| Erasca, Inc. | -125.04 Million USD | -81.17% |
| bluebird bio, Inc. | -211.91 Million USD | -6.902% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -4430.33% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 235.13% |
| DBV Technologies S.A. | -72.72 Million USD | -211.497% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -4430.33% |
| Moderna, Inc. | -4.71 Billion USD | 95.194% |
| Vincerx Pharma, Inc. | -40.15 Million USD | -464.133% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -3878.556% |
| Molecular Templates, Inc. | -8.12 Million USD | -2688.516% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | -275.139% |
| Travere Therapeutics, Inc. | -111.39 Million USD | -103.358% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | -67.37% |
| Spruce Biosciences, Inc. | -47.91 Million USD | -372.754% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | -60.179% |
| Cogent Biosciences, Inc. | -192.41 Million USD | -17.738% |
| MacroGenics, Inc. | -9.05 Million USD | -2400.983% |
| RenovoRx, Inc. | -10.23 Million USD | -2114.025% |
| Adicet Bio, Inc. | -142.65 Million USD | -58.799% |
| Prime Medicine, Inc. | -198.13 Million USD | -14.337% |
| Aditxt, Inc. | -32.38 Million USD | -599.608% |
| Adagene Inc. | -18.94 Million USD | -1095.686% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2998.298% |
| Quantum-Si incorporated | -95.96 Million USD | -136.076% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | -90.323% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -1454.003% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 271.192% |
| SciSparc Ltd. | -5.12 Million USD | -4322.862% |
| Vericel Corporation | -3.18 Million USD | -7019.39% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -188283.754% |
| Minerva Neurosciences, Inc. | -30 Million USD | -654.995% |
| Generation Bio Co. | -126.61 Million USD | -78.924% |
| Astria Therapeutics, Inc. | -72.89 Million USD | -210.791% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | -174.786% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 13.581% |
| Invivyd, Inc. | -198.64 Million USD | -14.043% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 33.755% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -2507.921% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 1093.331% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -2194.298% |
| 2seventy bio, Inc. | -217.57 Million USD | -4.122% |
| ADMA Biologics, Inc. | -28.23 Million USD | -702.22% |
| Clene Inc. | -49.5 Million USD | -357.618% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | -916.438% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | -358.266% |
| GeoVax Labs, Inc. | -25.96 Million USD | -772.419% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 30.947% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | -596.124% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 1097.091% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | -129.31% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | -203.046% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | -40.878% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 63.168% |
| Evaxion Biotech A/S | -22.12 Million USD | -923.905% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | -180.592% |
| Verve Therapeutics, Inc. | -200.06 Million USD | -13.231% |
| Trevena, Inc. | -40.28 Million USD | -462.285% |
| Surrozen, Inc. | -43.04 Million USD | -426.321% |
| Tyra Biosciences, Inc. | -69.13 Million USD | -227.681% |
| Cingulate Inc. | -23.53 Million USD | -862.564% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -3177.474% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -468.337% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -2837.993% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | -151.124% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | -269.642% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | -280.719% |
| Clearmind Medicine Inc. | -11.95 Million USD | -1794.926% |
| Kronos Bio, Inc. | -112.67 Million USD | -101.059% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | -227.383% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -8932015.778% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -163.739% |
| Statera Biopharma, Inc. | -174.4 Million USD | -29.89% |
| ImmunityBio, Inc. | -583.19 Million USD | 61.156% |
| Korro Bio, Inc. | -81.17 Million USD | -179.085% |
| Kineta, Inc. | -14.09 Million USD | -1506.774% |
| BioVie Inc. | -32.12 Million USD | -605.278% |
| Codexis, Inc. | -76.24 Million USD | -197.139% |
| Celularity Inc. | -196.29 Million USD | -15.407% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | -5.598% |
| Celcuity Inc. | -63.77 Million USD | -255.193% |
| Virax Biolabs Group Limited | -6.73 Million USD | -3264.339% |
| Cibus, Inc. | -267.62 Million USD | 15.353% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | -461.769% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -532.596% |
| IN8bio, Inc. | -30 Million USD | -654.954% |
| Kodiak Sciences Inc. | -260.49 Million USD | 13.034% |
| Annexon, Inc. | -134.23 Million USD | -68.76% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | -93.35% |
| Assembly Biosciences, Inc. | -61.22 Million USD | -269.992% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | -618.168% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 38.152% |
| Eyenovia, Inc. | -27.26 Million USD | -730.997% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 1149.229% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -42243.738% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | -196.501% |
| Arcellx, Inc. | -70.69 Million USD | -220.468% |
| Cardiff Oncology, Inc. | -41.44 Million USD | -446.654% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | -69.291% |
| Regulus Therapeutics Inc. | -30.03 Million USD | -654.2% |
| Moolec Science SA | -51.78 Million USD | -337.428% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | -332.566% |
| Geron Corporation | -184.12 Million USD | -23.034% |
| LAVA Therapeutics N.V. | -41.97 Million USD | -439.713% |
| Royalty Pharma plc | 1.13 Billion USD | 119.962% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | -66.627% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -2447.729% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | -966.406% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | -31.962% |
| Humacyte, Inc. | -110.77 Million USD | -104.502% |
| Structure Therapeutics Inc. | -89.62 Million USD | -152.777% |
| 89bio, Inc. | -142.18 Million USD | -59.322% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | -228.508% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -2083.088% |
| Genelux Corporation | -28.29 Million USD | -700.576% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | -679.422% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | -27.902% |
| Notable Labs, Ltd. | -11.26 Million USD | -1911.177% |
| Liquidia Corporation | -78.5 Million USD | -188.577% |
| Mustang Bio, Inc. | -51.6 Million USD | -339.012% |
| Immunovant, Inc. | -259.33 Million USD | 12.647% |
| Quantum-Si incorporated | -95.96 Million USD | -136.076% |
| Arbutus Biopharma Corporation | -72.84 Million USD | -210.971% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | -1068.872% |
| Vera Therapeutics, Inc. | -95.99 Million USD | -136.003% |
| Acasti Pharma Inc. | -12.85 Million USD | -1662.538% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | -908.729% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -1319.27% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | -24.204% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -5166.491% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | -1716.672% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | -668.163% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | -481.048% |
| PepGen Inc. | -78.62 Million USD | -188.122% |
| Moleculin Biotech, Inc. | -29.76 Million USD | -660.99% |
| United Therapeutics Corporation | 984.8 Million USD | 123.004% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | -917.695% |
| Solid Biosciences Inc. | -96.01 Million USD | -135.941% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -4627.968% |
| Immuneering Corporation | -53.47 Million USD | -323.662% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -4353.267% |
| Silo Pharma, Inc. | -3.7 Million USD | -6021.546% |
| Belite Bio, Inc | -31.63 Million USD | -616.17% |
| XOMA Corporation | -40.83 Million USD | -454.821% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | -316.7% |
| Bionomics Limited | -15.49 Billion USD | 98.538% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -169.737% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -676.963% |
| uniQure N.V. | -308.47 Million USD | 26.562% |
| Cassava Sciences, Inc. | -97.21 Million USD | -133.024% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2998.298% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | -83.536% |
| Forte Biosciences, Inc. | -31.47 Million USD | -619.72% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -2662.097% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | -679.342% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -42243.738% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -763.598% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | -1274.213% |
| Altimmune, Inc. | -88.44 Million USD | -156.13% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -49.448% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -676.963% |
| Compugen Ltd. | -18.75 Million USD | -1107.95% |
| Peak Bio, Inc. | -1259.26 USD | -17989751.182% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | -391.952% |
| Benitec Biopharma Inc. | -21.75 Million USD | -941.511% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 33.133% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | -173.09% |
| Zura Bio Limited | -60.36 Million USD | -275.313% |
| PolyPid Ltd. | -23.86 Million USD | -849.252% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | -1339.989% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | -173.09% |
| Instil Bio, Inc. | -156.08 Million USD | -45.136% |
| argenx SE | -295.05 Million USD | 23.221% |
| Immunome, Inc. | -106.8 Million USD | -112.103% |
| Compass Therapeutics, Inc. | -42.49 Million USD | -433.108% |
| Verona Pharma plc | -54.36 Million USD | -316.669% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | -126.727% |
| Shattuck Labs, Inc. | -87.29 Million USD | -159.501% |
| CervoMed Inc. | -2.17 Million USD | -10330.582% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | -81.739% |
| Plus Therapeutics, Inc. | -13.31 Million USD | -1601.254% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | -420.122% |
| Moolec Science SA | -51.78 Million USD | -337.428% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -1310000.262% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | -67.661% |
| AnaptysBio, Inc. | -163.61 Million USD | -38.455% |
| Design Therapeutics, Inc. | -66.86 Million USD | -238.816% |
| Leap Therapeutics, Inc. | -81.41 Million USD | -178.256% |
| NeurAxis, Inc. | -14.62 Million USD | -1448.806% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | -498.012% |
| Lumos Pharma, Inc. | -34.03 Million USD | -565.626% |
| Achilles Therapeutics plc | -69.66 Million USD | -225.183% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | -126.727% |
| 180 Life Sciences Corp. | -19.93 Million USD | -1036.382% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 7629.239% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -8932015.778% |
| Nutriband Inc. | -5.48 Million USD | -4029.919% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | -124.971% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | -366.063% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | -193.859% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | -566.88% |
| MoonLake Immunotherapeutics | -36 Million USD | -529.148% |
| Palisade Bio, Inc. | -12.3 Million USD | -1741.78% |
| Tourmaline Bio, Inc. | -42.12 Million USD | -437.791% |
| Beam Therapeutics Inc. | -132.52 Million USD | -70.938% |
| Neurogene Inc. | -36.31 Million USD | -523.782% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | -38.628% |
| AEON Biopharma, Inc. | -52.55 Million USD | -331.043% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | -130.816% |
| Sesen Bio, Inc. | -19.88 Million USD | -1039.303% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | -216.466% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | -1710.3% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 48.982% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | -103.054% |
| Athira Pharma, Inc. | -117.67 Million USD | -92.517% |
| Vaccinex, Inc. | -20.25 Million USD | -1018.656% |
| HCW Biologics Inc. | -24.99 Million USD | -806.363% |
| XOMA Corporation | -40.83 Million USD | -454.821% |
| Nektar Therapeutics | -276.05 Million USD | 17.937% |
| Arvinas, Inc. | -367.3 Million USD | 38.323% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -336385.704% |
| Merus N.V. | -154.93 Million USD | -46.212% |
| Omega Therapeutics, Inc. | -97.42 Million USD | -132.519% |
| Quince Therapeutics, Inc. | -31.38 Million USD | -621.807% |
| Rezolute, Inc. | -68.45 Million USD | -230.912% |
| Clene Inc. | -49.5 Million USD | -357.618% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -1368.794% |
| BeyondSpring Inc. | -21.02 Million USD | -977.423% |
| Synlogic, Inc. | -57.28 Million USD | -295.48% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | -1803.529% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -1992.546% |
| Peak Bio, Inc. | -1259.26 USD | -17989751.182% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | -506.238% |
| Krystal Biotech, Inc. | 10.93 Million USD | 2172.256% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | -58.309% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 30.318% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -4804.54% |
| MannKind Corporation | -11.93 Million USD | -1797.629% |
| Ikena Oncology, Inc. | -68.16 Million USD | -232.334% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | -977.987% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | -143.766% |
| Gossamer Bio, Inc. | -179.81 Million USD | -25.983% |
| CohBar, Inc. | -11.96 Million USD | -1793.803% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | -778.467% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -651.373% |
| Legend Biotech Corporation | -518.25 Million USD | 56.288% |
| Mural Oncology plc | -207.44 Million USD | -9.203% |
| Biora Therapeutics, Inc. | -124.11 Million USD | -82.523% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -1138.613% |
| Disc Medicine, Inc. | -76.42 Million USD | -196.405% |
| Champions Oncology, Inc. | -7.27 Million USD | -3013.51% |
| REGENXBIO Inc. | -263.49 Million USD | 14.025% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | -2034.528% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -376.874% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | -496.414% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | -126.17% |
| Vaxart, Inc. | -82.46 Million USD | -174.709% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 67974.21% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | -503.42% |
| Cellectis S.A. | -101.05 Million USD | -124.165% |
| Longeveron Inc. | -21.41 Million USD | -957.951% |
| Repare Therapeutics Inc. | -93.79 Million USD | -141.523% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 57.733% |
| Inozyme Pharma, Inc. | -71.16 Million USD | -218.311% |
| Revolution Medicines, Inc. | -436.36 Million USD | 48.085% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -3347.557% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | -634.944% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | -226.741% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | -249.964% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -2209.031% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 106.259% |
| Denali Therapeutics Inc. | -145.22 Million USD | -55.993% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -188283.754% |
| Veru Inc. | -93.15 Million USD | -143.191% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | -738.133% |
| Cingulate Inc. | -23.53 Million USD | -862.564% |
| Passage Bio, Inc. | -102.06 Million USD | -121.962% |
| Context Therapeutics Inc. | -23.96 Million USD | -845.322% |
| Exicure, Inc. | -16.91 Million USD | -1239.358% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | -19.915% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | -499.881% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -3381.293% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | -22.667% |
| Nuvalent, Inc. | -126.21 Million USD | -79.481% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -2054.302% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | -160.752% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | -641.681% |
| OmniAb, Inc. | -50.61 Million USD | -347.537% |
| Anew Medical, Inc. | 1.34 Million USD | 16928.972% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | -1311.898% |
| Lipocine Inc. | -16.35 Million USD | -1285.383% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | -241.204% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | -255.774% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -436.901% |
| G1 Therapeutics, Inc. | -47.96 Million USD | -372.281% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | -1042.348% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 58.164% |
| Ocugen, Inc. | -63.07 Million USD | -259.141% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | -136.639% |
| Q32 Bio Inc. | -112.96 Million USD | -100.546% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | -1217.7% |
| Alumis Inc. Common Stock | -154.99 Million USD | -46.161% |
| Equillium, Inc. | -13.33 Million USD | -1598.83% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | -275.276% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -2736.05% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | -1101.72% |
| Galera Therapeutics, Inc. | -59.08 Million USD | -283.432% |
| Evelo Biosciences, Inc. | -114.52 Million USD | -97.804% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -1132.667% |
| Dominari Holdings Inc. | -22.88 Million USD | -890.031% |
| Edesa Biotech, Inc. | -8.37 Million USD | -2605.132% |
| vTv Therapeutics Inc. | -20.25 Million USD | -1018.711% |
| Bio-Techne Corporation | 168.1 Million USD | 234.76% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 35.658% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 275.812% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | -85.944% |
| Candel Therapeutics, Inc. | -37.93 Million USD | -497.114% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | -101.114% |
| Nkarta, Inc. | -117.5 Million USD | -92.798% |
| BioCardia, Inc. | -11.57 Million USD | -1857.817% |
| Iterum Therapeutics plc | -38.37 Million USD | -490.391% |